AstraZeneca’s core numbers hide pharma firm’s progress

Not for the first time results today from AstraZeneca (AZ), the UK’s second-largest drug maker, are something of a curate’s egg. If there is cause for disappointment, it is that 2017 sales, at $22.5billion, were down 2% on 2016. Pascal Soriot, chief...

from http://ift.tt/2FIFrBz